When was the JZ modifier first introduced, and what are the requirements for reporting?
Medicare first introduced the JZ modifier on January 1, 2023; however, the modifier was not required for use until July 1, 2023, and Medicare began editing for use of the modifier on October 1 of the same year. Refer to MLN Matters Number MM13056 https://www.cms.gov/files/document/mm13056-new-jz-claims-modifier-certain-medicare-part-b-drugs.pdf. This modifier is required on any outpatient hospital 1450 claim containing single-dose or single-use containers and packages where the billed HCPCS code is assigned to a status indicator K (Nonpass-Through Drugs and Nonimplantable Biologicals, Including Therapeutic Radiopharmaceuticals) or G (Pass-Through Drugs and Biologicals) paid as a separate APC under the OPPS. The main purpose of reporting the JZ modifier is to indicate to Medicare that the provider has administered the entire vial or container of the single-dose or single-use drug to the beneficiary.
This question was answered in our Coding Essentials for Infusion & Injection Therapy Services. For more hot topics relating to infusion services, please visit our store or call us at 1.800.252.1578, ext. 2.
CPT® copyright 2025 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Celebrate Lab Week with MedLearn! Sign up to win one year of our Laboratory All Access Pass! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24